Other equities analysts have also issued reports about the stock. Robert W. Baird lowered shares of Vertex Pharmaceuticals from an outperform rating to a neutral rating and set a $250.00 target price on the stock. in a research report on Friday. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a buy rating to a hold rating and set a $279.00 target price on the stock. in a research report on Monday, April 4th. StockNews.com assumed coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, March 31st. They set a strong-buy rating on the stock. UBS Group raised their target price on shares of Vertex Pharmaceuticals from $258.00 to $325.00 in a research report on Wednesday, April 13th. Finally, JPMorgan Chase & Co. raised their target price on shares of Vertex Pharmaceuticals from $260.00 to $288.00 and gave the stock an overweight rating in a research report on Thursday, January 27th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of Buy and a consensus target price of $273.81.
Shares of Vertex Pharmaceuticals stock opened at $235.02 on Friday. The firm has a market capitalization of $60.06 billion, a P/E ratio of 24.74, a P/E/G ratio of 1.73 and a beta of 0.55. Vertex Pharmaceuticals has a 52 week low of $176.36 and a 52 week high of $292.75. The company has a quick ratio of 4.30, a current ratio of 4.46 and a debt-to-equity ratio of 0.05. The firm’s 50 day moving average is $260.93 and its two-hundred day moving average is $230.33.
In related news, EVP Bastiano Sanna sold 562 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, April 4th. The stock was sold at an average price of $267.71, for a total transaction of $150,453.02. Following the completion of the sale, the executive vice president now owns 43,343 shares in the company, valued at approximately $11,603,354.53. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Stuart A. Arbuckle sold 306 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, May 2nd. The stock was sold at an average price of $263.98, for a total value of $80,777.88. Following the sale, the chief operating officer now owns 64,760 shares of the company’s stock, valued at approximately $17,095,344.80. The disclosure for this sale can be found here. Insiders have sold a total of 45,828 shares of company stock valued at $12,464,221 in the last ninety days. Corporate insiders own 0.40% of the company’s stock.
A number of institutional investors have recently bought and sold shares of VRTX. Concord Wealth Partners increased its position in Vertex Pharmaceuticals by 750.0% during the 4th quarter. Concord Wealth Partners now owns 119 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 105 shares in the last quarter. First PREMIER Bank purchased a new stake in Vertex Pharmaceuticals during the 4th quarter worth about $27,000. Hudock Inc. increased its position in Vertex Pharmaceuticals by 156.3% during the 3rd quarter. Hudock Inc. now owns 164 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 100 shares in the last quarter. Moors & Cabot Inc. purchased a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $29,000. Finally, JJJ Advisors Inc. grew its holdings in Vertex Pharmaceuticals by 101.5% in the 4th quarter. JJJ Advisors Inc. now owns 133 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 67 shares during the period. Hedge funds and other institutional investors own 89.84% of the company’s stock.
Vertex Pharmaceuticals Company Profile (Get Rating)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
- Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
- Johnson Outdoors Falls On Bleak Outlook
- Institutional Support For Tyson Foods Is Growing
- Time to Buy These 3 Oversold Mid-Caps
- Littelfuse Stock is Hitting on All Cylinders
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.